🇺🇸 Induction- PF-06480605 150 mg SC Q4W in United States

Induction- PF-06480605 150 mg SC Q4W (induction-pf-06480605-150-mg-sc-q4w) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

Induction- PF-06480605 150 mg SC Q4W in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in United States

Frequently asked questions

Is Induction- PF-06480605 150 mg SC Q4W approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Induction- PF-06480605 150 mg SC Q4W in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does Induction- PF-06480605 150 mg SC Q4W cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.